Clinical Trial Update: Open Label Extension for GLYX13-C-202, NCT01684163 [Phase 2]

View source ↗

Summary

Open-label extension of a Phase 2 study for GLYX13 in major depressive disorder has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• GLYX13 (unnlisted)

Snippet

Sponsor: Naurex, Inc, an affiliate of Allergan plc | Conditions: Major Depressive Disorder | Phase 2 | Status: TERMINATED | Results posted: 2019-11-27